Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | HTT | P42858 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | QPCT | Q16769 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25474697 | 0.85 | LMNA (0.57) | SMN1; SMN2LMNAMAPTALOX12HPGD | |
| SCHEMBL17982696 | 0.81 | LMNA (0.65) | SMN1; SMN2LMNAMAPTALOX12HPGD | |
| SCHEMBL19726685 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAMAPTALOX12HPGD | |
| SCHEMBL15739655 | 0.81 | P2RY6 (0.75) | SMN1; SMN2LMNAMAPTALOX12HPGD | |
| SCHEMBL21338327 | 0.80 | LMNA (0.51) | SMN1; SMN2LMNAMAPTALOX12HPGD | |
| SCHEMBL25840781 | 0.79 | RECQL (0.56) | SMN1; SMN2LMNAMAPTALOX12HPGD | |
| SCHEMBL11772198 | 0.77 | CDK1 (0.63) | SMN1; SMN2LMNAMAPTALOX12HPGD | |
| SCHEMBL25517525 | 0.77 | CYP1A2 (0.72) | SMN1; SMN2LMNAMAPTALOX12MEN1 | |
| SCHEMBL27941612 | 0.77 | RECQL (0.54) | SMN1; SMN2LMNAMAPTALOX12MEN1 | |
| SCHEMBL29043442 | 0.76 | RECQL (0.53) | SMN1; SMN2LMNAMAPTALOX12HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11691997-B2 | Macrocycles | LUMIPHORE, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170183365-A1 | MACROCYCLES | LUMIPHORE, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20160221971-A1 | DI-MACROCYCLES | LUMIPHORE, INC. (US) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221971-A1 | DI-MACROCYCLES | DLD, NDC1, MCL1 | SMN1; SMN2 3304/4885LMNA 3243/4885MAPT 1196/4885 |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | SMN1; SMN2 2230/4885LMNA 1626/4885MAPT 1163/4885 |
| US-11691997-B2 | Macrocycles | HCCS, ABCB7, AURKAIP1 | SMN1; SMN2 2561/4885LMNA 3079/4885MAPT 1131/4885 |
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | SMN1; SMN2 3628/4885LMNA 3330/4885MAPT 2173/4885 |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | SMN1; SMN2 3628/4885LMNA 3330/4885MAPT 2173/4885 |
| US-20170183365-A1 | MACROCYCLES | HCCS, ABCB7, AURKAIP1 | SMN1; SMN2 2561/4885LMNA 3079/4885MAPT 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.